Multiple Myeloma and EasyM Resource Centre.
Featured
Comparison of EasyM Clonotypic Mass Spectrometry and EuroFlow MRD in Multiple Myeloma
wtang@rapidnovor.com2025-03-04T10:05:19-05:00March 3rd, 2025|Publication|
Mass Spectrometry Testing in Multiple Myeloma
wtang@rapidnovor.com2025-02-24T16:20:23-05:00February 11th, 2025|Articles|
M-spike and Multiple Myeloma
wtang@rapidnovor.com2025-02-24T16:20:40-05:00February 5th, 2025|Articles|
Publications, Posters & Case Studies
Comparison of EasyM Clonotypic Mass Spectrometry and EuroFlow MRD in Multiple Myeloma
wtang@rapidnovor.com2025-03-04T10:05:19-05:00March 3rd, 2025|Publication|
Measurable Residual Disease and Decision-Making in Multiple Myeloma
wtang@rapidnovor.com2025-02-28T09:22:26-05:00August 3rd, 2024|Case Studies|
Monitoring Minimal Residual Disease in Patients with Multiple Myeloma by Targeted Tracking Serum M-Protein Using Mass Spectrometry (EasyM)
wtang@rapidnovor.com2025-03-21T13:41:24-04:00March 21st, 2024|Publication|
Articles
What is Minimal Residual Disease?
wtang@rapidnovor.com2025-02-25T22:55:13-05:00February 24th, 2025|
Mass Spectrometry Testing in Multiple Myeloma
wtang@rapidnovor.com2025-02-24T16:20:23-05:00February 11th, 2025|
M-spike and Multiple Myeloma
wtang@rapidnovor.com2025-02-24T16:20:40-05:00February 5th, 2025|
Press & News
Monitoring Minimal Residual Disease in Blood with EasyM
wtang@rapidnovor.com2025-03-14T11:42:06-04:00July 19th, 2024|News|
Rapid Novor Teams Up with PMCC to Evaluate EasyM™ for Multiple Myeloma Minimal Residual Disease Monitoring
wtang@rapidnovor.com2025-02-24T16:13:03-05:00May 14th, 2024|News|
ASH 2023 | Dr. Ravi Vij – VJ HemeOnc
wtang@rapidnovor.com2025-03-21T11:58:09-04:00December 14th, 2023|News|
Rapid Novor’s Blood Test for Multiple Myeloma Monitoring is CLIA Certified for Clinical Use in the US
wtang@rapidnovor.com2025-02-28T09:24:46-05:00March 16th, 2023|News|
ASH 2022 | Dr. Ravi Vij – VJ HemeOnc
wtang@rapidnovor.com2025-03-21T11:58:31-04:00December 15th, 2022|News|